tbuckley/cabot-search huggingface dataset:
Intensity-modulated radiation therapy (IMRT) for prostate cancer: Toxicity and biochemical control in 183 Chinese patients from a single institution in Hong Kong.
Authors: D. M. Poon
Journal: Journal of Clinical Oncology (2011)

101 Background: To report the biochemical outcome and the acute and late toxicities in 183 Chinese patients with clinically localized prostate cancer treated with IMRT. Methods: Between May 2001 and November 2009, 183 patients with clinically localized prostate cancer were treated with IMRT at the Prince of Wales Hospital. Median follow-up was 44 months (range 8.5 to 112 months).Treatment was planned using an inverse-planning approach, and the beams were delivered by dynamic multileaf collimation. Four-field box technique was used for pelvic irradiation (pelvic RT) if indicated in phase I and IMRT was used for prostate boost in phase II. The median age of the patients was 71.4 (range 45 to 82). According to the NCCN risk classification, 18 (9.8%), 47 (25.7%) and 118 (64.5%) patients belong to favorable, intermediate, and unfavorable risk group respectively. The median prescription dose of the planning target volume of the prostate gland (PTV-G) is 72Gy (range from 66 to 76Gy). 77 patients (42.1%) received pelvic RT. 129 patients (70%) received neoadjuvant hormone and 106 patients (57.9%) received adjuvant hormone. Acute and late toxicities were scored according to the Common Terminology Criteria for Adverse Events Version 4.02. Biochemical failure was defined according to the Houston definition (absolute PSA nadir plus 2ng/ml dated at the call). Results: The 5-year actuarial biochemical-failure free survival for patients in favorable, intermediate and unfavorable risk groups were 95%, 80%, and 83% respectively. 3 patients (1.6%) experienced grade 3 acute gastrointestinal (GI) toxicity. There were no grade 3 acute genitourinary (GU) toxicity. There was no grade 4 acute GI or GU toxicity. 14 patients (7.7%) developed grade 2 late GI toxicity and 8 patients (4.4%) developed grade 3 late GI toxicity. 5 patients (2.7%) developed grade 2 late GU toxicity and 5 patients (2.7%) developed grade 3 late GU toxicity. There was no grade 4 late GI or GU toxicity. Conclusions: These data demonstrate that IMRT for prostate cancer is feasible and safe in Chinese population. The early biochemical outcome is encouraging and the grade 3 late GI and GU complications were below 5%. No significant financial relationships to disclose.
Demonstration of Biclonal Chronic Lymphocytic Leukemia with Mutated and Unmutated Clones and Concurrent but Clonally Unrelated Myeloma in the Same Patient by Single Cell Immunoglobulin Heavy and Light Chain Gene Analysis.
Authors: Selim A. Yavuz, Dan-Paul Hartmann, Said Baidas, Peter E. Lipsky, Metin Ozdemirli
Journal: Blood (2004)
Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Using Oral Fludarabine as Part of the Conditioning Regimen.
Authors: Julio Delgado, Ana Marco, Estela Moreno, Jose L. Pinana, David Valcarcel, Rocio Parody, Blanca Sanchez-Gonzalez, Rodrigo Martino, Javier Briones, Anna Sureda, Salut Brunet, Jorge Sierra
Journal: Blood (2007)
Exclusive chemoradiotherapy without TURBT for frail and elderly patients with an invasive bladder cancer: Which platin fits better?
Authors: C. Khoury, E. Martin, M. Gauthier, G. Crehange, S. Ladoire, L. Cormier, F. Bonnetain, J. Miny, J. Bosset, P. Maingon
Journal: Journal of Clinical Oncology (2011)

279 Background: Frail and elderly patients (pts) with invasive bladder carcinoma (BC) are often unfit for surgery. Whether exclusive concomitant chemoradiotherapy (cCRT) without TURBT could be performed in a curative-intent remains uncertain. Methods: From 1996 to 2007, 68 pts were treated with exclusive cCRT. Median age was 77.5 years (70-91). WHO performance status (PS) at baseline were: PS 0: 27 pts; PS 1: 36 pts; PS 2; 4 pts; PS 3: 1 pt. 31 pts (45.5%) had a Charlson's score ≥ 5. Tumors were staged T1 (5 pts), T2 (44 pts), T3 (13 pts) and T4 (6 pts). 87.5% of the pts were clinically staged N0. Transuretral resection bladder tumor (TURBT) was incomplete and thus done for a diagnostic purpose only. 58 pts had an urothelial tumor (85.29%). External radiotherapy (ERT) was delivered with 1.8-2.0 daily fractions: median total dose of 63Gy [18Gy-69.4Gy] to the bladder and 92% of the pts had a whole pelvic ERT: median dose: 37.2Gy [18Gy-46Gy]. Drug was either cisplatin (CDDP) for 40 pts or carboplatin (CBDCA) for 28 pts. Overall survival (OS) and progression-free survival (PFS) rates were evaluated. Results: The rate of compliant pts with the full course of cCRT was 77.9% (53 pts). 5 pts stopped cCRT for acute urinary adverse events (AE) whereas 8 pts stopped chemotherapy only for hematological or renal biochemical AE. For late toxicity, 5 pts had a G3/4 toxicity (1 rectal bleeding, 1 urinary bleeding, 1 recto-urinary fistula, 1 urinary incontinence and 1 urinary retention). Median follow-up was 4.6 years [CI95%: 3.43-5.93]. Of the 68 pts, 14 are alive (13 recurrence-free) amongst the 61 evaluable pts and 47 have died (24 recurrence-free). OS rates at 2 and 5 years were 50% (CI95%: [37.45%-61.44%]) and 31% (CI95%: [13.67%-38.43%]). PFS rates at 2 and 5 years were 37.4% [CI95%: 25.89%-48.82%] and 22% [CI95%: 12.25%- 33.61%], respectively. OS and PFS rates were worse for pts treated with CBDCA in comparison with those treated with CDDP (p= 0.01 for OS and p= 0.03 for PFS). Combined 5-FU did not impact either OS or PFS. Conclusions: cCRT for elderly pts with a BC was feasible. For selected pts with a good PS, the adequate drug that should be combined with a conventional full course of ERT remains CDDP. No significant financial relationships to disclose.
A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas.
Authors: S. Attia, M. R. Mahoney, S. H. Okuno, D. Adkins, H. G. Ahuja, T. P. Ducker, W. J. Maples, L. Ochs, N. L. Wentworth-Hartung, C. Erlichman, H. H. Bailey
Journal: Journal of Clinical Oncology (2011)

10075 Background: Two patients with advanced unclassifiable soft tissue sarcoma had tumor shrinkage on a phase I study of vorinostat with bortezomib. Therefore, we assessed this combination in a single-arm phase II investigational study in advanced soft tissue sarcoma patients. Methods: Adults with advanced soft tissue sarcoma, an ECOG performance status ≤ 1, and no more than one prior systemic treatment for advanced stage were eligible. Patients received vorinostat 400 mg orally days 1-14 and bortezomib 1.3 mg/m2 intravenously days 1, 4, 8 and 11 of a 21-day cycle. The primary endpoint was confirmed response rate. Secondary endpoints included toxicity, progression-free survival (PFS) and overall survival (OS). Results: Sixteen patients were enrolled (median age, 62 years; 11 (62%) were women). A total of 53 cycles were received (median, 2 cycles). Fourteen patients were evaluable for response. No confirmed responses were observed, prompting study closure. One patient with synovial sarcoma had a minor response. Six patients had stable disease as best response, including one patient with low-grade myxosarcoma lasting 11 cycles. Median PFS was 1.5 months (95% CI: 1.3-2.9 months) and 6-month OS rate was 85%(95% CI: 67-100%)). Two patients have died, unrelated to treatment. Grade 3 or 4 toxicities, at least possibly related to treatment, included thrombocytopenia (6 patients), diarrhea (6 patients) and fatigue (3 patient). Conclusions: Despite phase I activity with this combination in advanced soft tissue sarcoma, no responses were noted in the phase II setting. Supported by N01-CM-62205.
Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)
Authors: Sandra Malak, Pascale Cony-Makhoul, Jean-Christophe Ianotto, Dana Ranta, Philippe Rodon, Fabienne Vacheret, Barraco Fiorenza, Francoise Boyer, Katell Le Du, Loic Garcon, Francois Lefrere, Mathieu Wemeau, Valerie Ugo, Jean-Jacques Kiladjian, Lydia Roy
Journal: Blood (2016)
Patient-reported toxicity after treatment for prostate cancer (PC).
Authors: Christine E. Hill-Kayser, Carolyn Vachani, Margaret K. Hampshire, Gloria A DiLullo, James M. Metz
Journal: Journal of Clinical Oncology (2012)

221 Background: PC patients may be at risk for significant late effects after treatment, the impact of which may difficult to evaluate in the clinical setting. This Internet based study evaluates patient perceptions of toxicity after treatment for PC. Methods: Patient-reported data was gathered via a convenience sample frame from PC survivors voluntarily utilizing a publically available, free, Internet-based tool for creation of survivorship care plans. Available at www.livestrongcareplan.com, the tool allows survivors to enter data regarding diagnosis, demographics, and treatments, and provides customized guidelines for future care. During use of the tool, PC survivors are queried regarding late effects associated with specific treatments, and asked to answer “yes,” “no,” or “I don’t know.” They are also asked to score urinary and sexual symptoms using adapted scales. Results: Of 4378 survivors using this tool from 4/10-7/11, 203 (5%) had a diagnosis of PC. Median diagnosis age was 59 and median current age 63. 47% reported having undergone radical prostatectomy (RP) and 53% radiation (RT). RT was delivered via x-ray (80%), brachytherapy (15%), protons (3%), and combinations (3%). Hormonal treatment was delivered to 50%. Erectile dysfunction was reported by 65% of PC survivors using this tool, 80% of those having undergone RP, and 52% of those RT. Of men reporting ED, 97% reported that they could have an erection prior to PC treatment. Survivors treated with RP most commonly reported urinary incontinence (42%) and dry ejaculation (27%). Survivors treated with RT reported urinary incontinence (14%) and chronic diarrhea (10%). Most (75%) survivors reported they would share the care plan with their healthcare team; of 25% who reported that they would not, the most common reason was “I did not think they would care.” Conclusions: Survivors using this tool anonymously and voluntarily report significant toxicity after PC treatment, including ED and urinary incontinence. Not all survivors appear comfortable discussing these issues with healthcare providers. This tool offers a unique way for survivors to report their experiences; the data reported here may be of significant impact in future study of quality of life, patient counseling and survivor care.
Successful High-Dose Ribavirin Treatment of Respiratory Syncytial Virus-Induced Tracheobronchitis and Pneumonia Occuring Pre-Engraftment in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Authors: Saskia Gueller, Ulrich Duenzinger, Timo Wolf, Sabine Mousset, Hans Martin, Hubert Serve, Gesine Bug
Journal: Blood (2009)
UK is ranked 15th for heart care in European index
Authors: Jacqui Wise
Journal: BMJ (2016)

The United Kingdom has been ranked 15th of 30 European countries for cardiovascular healthcare, mainly because prevention efforts are hampered by high consumption of alcohol and sugar. The latest Euro Heart Index 2016 put France at the top of the table, closely followed by Norway and Sweden.

The index, produced by the Health Consumer Powerhouse,1 is based on 31 indicators covering four key areas of cardiovascular health: prevention, procedures, access to care, and outcomes. For each indicator a country is rated green (3 points), amber (2), or …
Acute Myeloid Leukemia Remission Bone Marrow Reveals the Presence of Malignant and Normal Side Population (SP) Stem Cells Whose Frequencies and Ratios Predict Clinical Outcome.
Authors: Bijan Moshaver, Marjolein A. van der Pol, Guus H. Westra, Nicole Feller, Angele Kelder, Anna van Rhenen, Gert J. Ossenkoppele, Sonja Zweegman, Gerrit J. Schuurhuis
Journal: Blood (2006)
Greek Registry of Myelofibrosis: Baseline Characteristics and Therapeutic Strategy
Authors: Damianos Sotiropoulos, Argiris S. Symeonidis, Vassilios K Papadopoulos, Panagiotis Tsirigotis, Theodoros Iliakis, Konstantinos Gkirkas, Aggeliki Vourtsi, Anastasia Marvaki, Emmanouil Papadakis, Dimitrios Kokkinidis, Maria Kotsopoulou, Maria Dimou, Panagiotis Zikos, Evangelia Tzouvara, Alexandra Kouraklis, Efthymia Vlachaki, Nikolaos Anagnostopoulos, Achilles Anagnostopoulos, Maria Pagoni, Nora-Athina Viniou, Theodoros Marinakis, Panayiotis Panayiotidis, Constantinos Tsatalas
Journal: Blood (2014)
Surrogate Outcome Measures of In Vitro Osteoclast Resorption of β Tricalcium Phosphate
Authors: Susan A. Clarke, Joanne Martin, John Nelson, Jean‐Christophe Hornez, Marc Bohner, Nicholas Dunne, Fraser Buchanan
Journal: Advanced Healthcare Materials (2016)

Introduction of porosity to calcium phosphate scaffolds for bone repair has created a new challenge when measuring bioresorption in vitro, rendering traditional outcome measures redundant. The aim of this study is to identify a surrogate endpoint for use with 3D scaffolds. Murine RAW 264.7 cells are cultured on dense discs of β-tricalcium phosphate in conditions to stimulate osteoclast (OC) formation. Multinucleated OCs are visible from day 6 with increases at days 8 and 10. Resorption pits are first observed at day 6 with much larger pits visible at days 8, 10, and 12. The concentration of calcium ions in the presence of cells is significantly higher than cell-free cultures at days 3 and 9. Using linear regression analysis, Ca ion release could account for 35.9% of any subsequent change in resorption area. The results suggest that Ca ion release is suitable to measure resorption of a beta-tricalcium phosphate ceramic substrate in vitro. This model could replace the more accepted resorption pit assay in circumstances where quantification of pits is not possible, e.g., when characterizing 3D tissue engineered bone scaffolds.
Altered mRNA Expression of Pax-5 Is a Common Event in Acute Lymphoblastic Leukemia.
Authors: Alessandra Santoro, Lea Dagnino, Cecilia Agueli, Domenico Salemi, Maria Grazia Bica, Annalisa Marfia, Sonia Cannella, Marinella Veltroni, Valentina Cetica, Emanuela Giarin, Francesco Fabbiano, Giuseppe Basso, Maurizio Arico
Journal: Blood (2008)
Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group
Authors: Kara M. Kelly, Peter D. Cole, Lu Chen, Kenneth B Roberts, David C. Hodgson, Kathleen McCarten, Steve Y Cho, Cindy Schwartz
Journal: Blood (2015)
Detection of resectable pancreatic cancer with SOMAmer proteomic technology.
Authors: Randall Brand, Malte Buchholz, Mike Mehan, David C. Whitcomb, Herbert Zeh, Arthur J Moser, Thomas M Gress, Steve Williams, Maria dela Cruz, Rachel Ostroff
Journal: Journal of Clinical Oncology (2012)

162 Background: To improve the current dismal 5-year survival rates for pancreatic adenocarcinoma (PC) it is essential to develop strategies focused on detection in high-risk populations. This study employed a unique SOMAmer proteomics platform to identify a biomarker panel that discriminates between pancreatic cancer and control patients. A secondary goal was to compare the panel with CA 19-9. Methods: Plasma samples (total &lt; 20 ul) were analyzed for 825-proteins using a SOMAmer proteomics platform on training set of 100 cases and 69 controls from a single institution. The control group contained individuals with GI symptoms, including acute and chronic pancreatitis, and normal controls. An independent blinded validation set from another center consisted of 43 PC patients and 47 controls. About two thirds (96/143) of the study cases were in resectable stages I-IIb. Biomarkers were identified by Random Forest backwards selection, using a false-discovery-rate corrected value of p&lt;0.001. CA19-9 levels were available on a subset of the patients from the training set (87 PC and 29 controls). A CA 19-9 level of &gt; 40 U/ml was defined as positive. Results: In the training set, 37 markers were significantly different between case and controls. A 10 marker Random Forests classifier had an AUC of 0.91 for training and 0.90 for the independent validation set. Comparison of the SOMAmer results with CA 19-9 levels are shown in the table. There was 78% agreement between the two tests. One could maximize sensitivity with some sacrifice of specificity by combining either test positive (95% and 66%, respectively) or conversely maximize specificity (97%) with lower sensitivity of 77% if both tests must be positive. Conclusions: 1) The 10 marker SOMAmer biomarker panel is promising for the detection of resectable pancreatic cancer with an AUC of 0.91 on a training set, which was confirmed on an independent validation set. 2) Preliminary data suggests that this test is complementary to CA 19-9 with improved combined sensitivity of up to 95%. 3) Studies to assess further applications of these panels, including for risk assessment in individuals with a family history of pancreatic cancer, are underway. [Table: see text]
Metadherin/Astrocyte elevated gene-1 positively regulates the stability and function of forkhead box M1 during tumorigenesis
Authors: Lixuan Yang, Kejun He, Sheng Yan, Yibing Yang, Xinya Gao, Maolei Zhang, Zhibo Xia, Zhengsong Huang, Suyun Huang, Nu Zhang
Journal: Neuro-Oncology (2016)

Forkhead box M1 (FOXM1) is overexpressed and activates numerous oncoproteins in tumors. However, the mechanism by which the FOXM1 protein aberrantly accumulates in human cancer remains uncertain. This study was designed to clarify the upstream signaling pathway(s) that regulate FOXM1 protein stability and transcriptional activity.Mass spectrometry and immunoprecipitation were performed to identify the FOXM-metadherin (MTDH) interaction. In vivo and in vitro ubiquitination assays were conducted to test the effect of MTDH on FOXM1 stability. Chromatin immunoprecipitation assays were used to determine the involvement of MTDH in FOXM1 transcriptional activity. Cell invasion assays, tube formation assays, and in vivo tumor formation assays were performed to evaluate the cooperative activities of FOXM1 and MTDH during tumorigenesis.MTDH directly interacts with FOXM1 via the N-terminal inhibitory domain of MTDH, and this interaction disrupted the binding of cadherin-1 to FOXM1, thus protecting FOXM1 from subsequent proteasomal degradation. Deleting the MTDH-binding sites of FOXM1 abolished the MTDH overexpression-mediated stabilization of FOXM1. MTDH also bound to FOXM1 target gene promoters and enhanced FOXM1 transcriptional activity. MTDH knockdown destabilized FOXM1 and attenuated its transcriptional activity, consequently inhibiting cell cycle progression, angiogenesis, and cancer cell invasion in vitro and in vivo; these effects were abolished via forced overexpression of a stabilized mutant form of FOXM1. Thus, MTDH stabilized FOXM1 and supported the sustained activation of FOXM1 target genes.These findings highlight a novel MTDH-regulated mechanism of FOXM1 stabilization and provide profound insight into the tumorigenic events simultaneously mediated by FOXM1 and MTDH.
Innovative Hematopoietic Gene-Therapy Concepts for Hereditary Pulmonary Alveolar Proteinosis Utilizing Hematopoietic Stem Cell Derived Macrophages
Authors: Nico Lachmann, Christine Happle, Takuji Suzuki, Miriam Hetzel, Kevin A. Link, Adele Mucci, Paritha Arumugam, Jens Bankstahl, Dagmar Dilloo, Punam Malik, Carolyn Lutzko, Axel Schambach, Bruce Colston Trapnell, Gesine Hansen, Thomas Moritz
Journal: Blood (2015)
Is survival from resection of pancreatic adenocarcinoma with major arterial involvement any different than venous/minor arterial resection?
Authors: John T. Miura, Sam G Pappas, T. Clark Gamblin, Kiran Turaga
Journal: Journal of Clinical Oncology (2012)

310 Background: Major arterial involvement is considered a contraindication to surgical resection for pancreatic adenocarcinoma (PA). We hypothesized that survival for patients (pts) with T3 or T4 disease with major arterial involvement (SMA/Celiac Axis) undergoing pancreatic resection was worse than those undergoing venous resections. Methods: We included all pts with T3 or T4 PA in the SEER database from 2004-2007. Patients were divided into those involving the portal vein/SMV/GDA/hepatic artery and those involving the SMA and celiac axis. Non-surgical control arm (CA) included pts who were recommended surgery but did not undergo it. Multivariate survival analyses were performed using the cox-proportional hazards model. Results: We identified 571 pts, of whom 323(56%) underwent resection. Median disease specific survival of pts undergoing surgery with SMA, Celiac involvement was 12, 8 vs. 7, 6 months respectively in the CA(p=0.01). Pts undergoing venous resection had a longer survival than those undergoing arterial resection in multivariate models (18 vs. 12 months, p=0.001) Conclusions: Resection for pancreatic adenocarcinoma with major arterial involvement is associated with a poorer survival as compared to those with venous/minor arterial involvement. This study validates the current practice of considering major arterial involvement as a contraindication to resection. [Table: see text]
Utilization of neoadjuvant chemotherapy in stages II and III urothelial carcinoma of the bladder.
Authors: B. Huang, T. Tucker, J. R. Bylund, J. J. Rinehart, R. G. Rowland, S. E. Strup, P. L. Crispen
Journal: Journal of Clinical Oncology (2011)

292 Background: Level 1 evidence supports the use of neoadjuvant chemotherapy (NC) prior to cystectomy in patients with stage II and III urothelial carcinoma of the bladder. However, the utilization of NC in appropriate patients prior to cystectomy is unknown. Here we examine the use of and potential predictors for the use of NC prior to cystectomy. Methods: The Kentucky Cancer Registry was reviewed from the years 2000 to 2007 for patients undergoing cystectomy for stage II and III (T2-4aN0M0) bladder cancer. Histologic subtypes of bladder cancer other than urothelial carcinoma were excluded. Multiple logistic regression was utilized to examine factors associated with the use of neoadjuvant chemotherapy prior to cystectomy. Results: A total of 223 patients undergoing cystectomy during the study period were identified. Median age was 66 years and 74% of patients were male. The majority of patients, 66%, had AJCC stage II disease. 6.3% (14/223) of patients received NC prior to cystectomy. Bivariate analysis did not reveal significant differences in age, gender, stage, geographic location, or insurance status when comparing patients receiving and not receiving NC prior to cystectomy. Year of treatment was significantly associated with the use of NC with 2.8% and 9.6% of patients receiving NC between the years 2000–2003 and 2004–2007, respectively (p = 0.034). Year of diagnosis remained significantly associated with the use of NC on multiple logistic regression (OR 4.23, CI 1.12–15.9). Conclusions: Although a significant increase in the number of patients receiving NC prior to cystectomy has been observed since 2003, the overall utilization of NC remains low despite the proven survival benefit noted in randomized trials. Further investigation of the low utilization of NC in this population is warranted. No significant financial relationships to disclose.